Ownership Neutral

2026-08-26 15:44

- Dr. Reddy's Laboratories Ltd. allotted 4,110 equity shares (Re.1/- each) on August 26, 2026, to eligible employees under its ESOP Scheme. - Post-allotment, the total issued shares stand at 83,46,80,910.

Business Update Negative

2026-08-14 23:47

CRITICAL RED FLAG DETECTED

- USFDA completed a GMP inspection at Dr. Reddy's FTO-3 formulations manufacturing facility in Bachupally, Hyderabad from August 6-14, 2026. - The company received a Form 483 with four observations, which will be addressed within the stipulated timeline.

Business Update Positive

2026-08-14 23:07

- USFDA inspection at Dr. Reddy's Mirfield, UK API manufacturing facility classified as 'Voluntary Action Indicated (VAI)'. - The inspection is now officially closed.

Ownership Positive

2026-08-14 12:14

- ICICI Prudential Mutual Fund acquired 7,12,884 shares of Dr. Reddy's Laboratories Ltd. on August 12, 2026. This increased their total shareholding to 5.037%, exceeding the 5% threshold under SEBI SAST Regulations.

Governance Negative

2026-08-13 16:35

CRITICAL RED FLAG DETECTED

- Mr. Deepak Sapra has resigned from his position as CEO, API and Services and Senior Management Personnel of the company. - His resignation is effective from the close of business hours on November 12, 2026. - He is leaving to pursue opportunities outside the company.

Business Update Neutral

2026-08-07 23:31

- Dr. Reddy's terminated its agreement with Novartis India Limited (NIL), dated February 11, 2022, for distribution and promotion of select brands in India. This follows a change in NIL's controlling shareholding. The Company will commercialize the brands until September 30, 2026.

Business Update Neutral

2026-08-07 23:31

- Dr. Reddy's Laboratories terminated its agreement with Novartis India Limited (NIL) for the distribution and promotion of select brands in India. - The termination is due to a change in NIL's controlling shareholding. - Dr. Reddy's will continue commercializing these brands until September 30, 2026.

Business Update Neutral

2026-08-07 23:31

- Dr. Reddy's Laboratories terminated its distribution and promotion agreement with Novartis India Limited (NIL), originally dated February 11, 2022. - This follows a change in NIL's controlling shareholding. - Dr. Reddy's will continue commercializing the brands until September 30, 2026.

Business Update Positive

2026-08-01 09:44

- Dr. Reddy's Laboratories received U.S. FDA approval for its rituximab biosimilar on August 1, 2026. - Fresenius Kabi holds exclusive commercialization rights for the product in the United States. - The biosimilar further strengthens Dr. Reddy's global biosimilars portfolio.

Business Update Negative

2026-07-29 21:41

CRITICAL RED FLAG DETECTED

- USFDA completed a Pre-Approval and GMP inspection at Dr. Reddy's FTO-SEZ Process Unit-02, Srikakulam, from July 20-29, 2026. - A Form 483 with three observations was issued, which the company will address within the stipulated timeline.

Business Update Positive

2026-07-29 10:57

- Dr. Reddy's clarifies news regarding Thailand FDA approval for NUZOLVENCE® (zoliflodacin), an antibiotic, six months after US authorization. - The company stated this development does not constitute a material event requiring disclosure under Regulation 30.

Business Update Negative

2026-07-28 23:11

CRITICAL RED FLAG DETECTED

- Q1 FY27 consolidated revenues declined 5.6% YoY to ₹8,071 crores (US$853 million), impacted by lower lenalidomide sales and a ₹240 crore provision for semaglutide API challenges (rejected batches, lost PLI). - EBITDA margin was 12.5% (down 1416 bps YoY), primarily due to semaglutide issues and Middle East conflict; excluding this, it would be 15.4%. - Profit After Tax (PAT) for the quarter was ₹443 crores (US$47 million). - USFDA issued 7 observations during a Pre-License Inspection at a biologics manufacturing facility, which the company has responded to. - Management expects to resume semaglutide commercial supplies by November and maintains high-teens to 20% EBITDA margin guidance (excluding semaglutide impact) for the future. - Expressed confidence in a strong second half with double-digit base business growth and steady margin improvement. - Launched new complex generics including bosutinib (first-to-market with 180-day exclusivity) and nintedanib in the US.

Governance Neutral

2026-07-23 21:12

- Shareholders approved the re-appointment of Dr. K. P. Krishnan as an Independent Director for five years from January 7, 2027 to January 6, 2032. - Approved the appointment of Mr. Srikanth Velamakanni as an Independent Director for five years from July 1, 2026 to June 30, 2031. - Approved the appointment of M/s Deloitte Haskins & Sells, LLP as Statutory Auditors for a term of five consecutive years, commencing from the 42nd AGM.

Governance Positive

2026-07-23 21:08

- Dr. Reddy's Laboratories held its 42nd Annual General Meeting (AGM) on July 23, 2026. - Members adopted the Audited Financial Statements for the financial year ended March 31, 2026. - A final dividend of ₹8/- per equity share for FY2025-26 was declared. - Re-appointments and appointments of directors and auditors were approved. - All resolutions were passed by the requisite majority.

Governance Positive

2026-07-23 21:06

- The 42nd Annual General Meeting (AGM) of Dr. Reddy's Laboratories Limited was held on July 23, 2026. - All resolutions presented at the AGM were passed by the requisite majority. - Key resolutions passed include the adoption of financial statements for FY2026 and the declaration of a final dividend of Rs. 8/- per equity share for FY2026. - Re-appointments and appointments of directors and auditors were also approved.

Business Update Neutral

2026-07-23 08:10

- Audio recording of the Earnings Call conducted on July 22, 2026, for the quarter ended June 30, 2026, has been made available. - Weblink provided for access.

Governance Positive

2026-07-22 16:45

- Dr. Reddy's Board Committee approved the grant of 15,933 Indian Stock Options on July 22, 2026. - Options are under the Employees Stock Option Scheme, 2018, at an exercise price of ₹1,206/- per share, vesting 100% in 3 years.

Governance Neutral

2026-07-22 16:30

- Appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, effective July 22, 2026. - Approval of M/s Deloitte Haskins & Sells, LLP as Independent Registered Public Accounting Firm for a five-year term, subject to shareholder approval.

Financials Negative

2026-07-22 16:24

CRITICAL RED FLAG DETECTED

- Consolidated Revenue ₹8,070.5 Cr vs ₹8,545.2 Cr (▼5.6% YoY) - EBITDA ₹1,008.8 Cr vs ₹2,278.4 Cr (▼55.7% YoY) - PAT ₹443.5 Cr vs ₹1,417.8 Cr (▼68.7% YoY) - EBITDA Margin 12.5% vs 26.7% (▼1420bps) - Results include an adverse impact of ₹239.7 Cr provision related to semaglutide API issues.

Financials Negative

2026-07-22 16:19

CRITICAL RED FLAG DETECTED

- Consolidated Revenue ₹80,705 Mn vs ₹85,452 Mn (▼5.6% YoY) - EBITDA ₹10,088 Mn vs ₹22,784 Mn (▼55.7% YoY) - PAT ₹4,435 Mn vs ₹14,178 Mn (▼68.7% YoY) - EBITDA Margin 12.5% vs 26.7% (▼1420bps) - Q1FY27 results include an adverse impact of a ₹2,397 Mn provision related to semaglutide API issues. - The company received a USFDA Form 483 with seven observations for its biologics manufacturing facility.

Business Update Negative

2026-07-15 16:24

CRITICAL RED FLAG DETECTED

- Dr. Reddy's reported a temporary halt in commercial supplies of Semaglutide injection due to an impurity detected in scale-up batches of the API, causing the finished drug product to be out of specifications. - The company expects to resume commercial supply around late October/early November 2026, following process adjustments and re-validation, which are anticipated to take until the end of September. - The updated outlook for Semaglutide pen supply for FY27 is 6-7 million pens between Q3 and Q4, in addition to prior sales, a reduction from the previously guided 12 million pens. - There is no impact on patient safety, existing global regulatory filings, or the supply of Semaglutide oral tablets. - The issue may lead to a write-down of associated inventory and will be a downside to previous revenue expectations, though the long-term EBITDA margin target (20%+) remains unchanged.

Business Update Neutral

2026-07-13 14:36

- Concall Schedule - Concall Date: Wednesday, July 22nd, 2026 - Concall Time: 19:30 PM IST / 10:00 AM ET

Business Update Neutral

2026-07-10 08:47

- Audio recording of the conference call conducted on July 9, 2026, is now available. Weblink provided for access.

Business Update Negative

2026-07-09 09:37

- Dr. Reddy's reported that certain batches of semaglutide API were found out of specification, leading to delayed commercial supplies of the product. The company stated no impact on patient safety or existing global regulatory filings. - A conference call to discuss this issue is scheduled for Thursday, July 9, 2026, from 16:30 – 17:00 IST.

Business Update Negative

2026-07-09 09:17

CRITICAL RED FLAG DETECTED

- Dr. Reddy's announced certain batches of semaglutide were out of specification due to an API issue, causing delayed commercial supplies. No impact on patient safety or global regulatory filings. A conference call to discuss this issue is scheduled for July 9, 2026, 16:30 – 17:00 IST.

Governance Positive

2026-06-30 20:02

- The 42nd Annual General Meeting (AGM) will be held on Thursday, July 23, 2026, at 11:00 a.m. via Video Conferencing/OAVM. - The Board recommended a final dividend of ₹8 per equity share for FY 2025-26. - The record date for the dividend is Friday, July 10, 2026, with payment on or before July 30, 2026.

Business Update Positive

2026-06-30 19:29

- Filed Business Responsibility & Sustainability Report (BRSR) for FY2025-26. - Highlights include 80.1% employee ethical conduct training, 98% global waste diverted from landfill, and 78% electricity from renewable power. - The company reported a 50% absolute reduction in Scope 1&2 emissions from baseline year 2023 and aims to serve 1.5 billion patients by 2030.

Governance Positive

2026-06-30 19:24

- Notice of 42nd Annual General Meeting to be held on Thursday, July 23, 2026, at 11:00 A.M. IST via video conference. - Agenda includes adoption of financial statements for FY26, declaration of a final dividend of ₹8/- per equity share, re-appointment of directors, and appointment of Deloitte Haskins & Sells LLP as statutory auditors. - The cut-off date for e-voting is July 16, 2026, with voting from July 19-22, 2026. - Final dividend, if declared, will be paid on or before July 30, 2026.

Financials Negative

2026-06-30 19:15

CRITICAL RED FLAG DETECTED

- Consolidated Revenue ₹33,593.3 Cr vs ₹32,553.5 Cr (▲3.2% YoY) - EBITDA ₹7,659.5 Cr vs ₹9,213.3 Cr (▼16.9% YoY) - PAT ₹4,285 Cr vs ₹5,654.4 Cr (▼24.2% YoY) - EBITDA Margin 22.8% vs 28.3% (▼550bps)

500124

Dr Reddys Laboratories Ltd

Price Chart

Filing History

Unlock Full History